Literature DB >> 23389285

Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?

H Ishida1, K Kumamoto, K Ishibashi, S Hatano, T Matsuzawa, N Okada, Y Kumagai, H Baba, N Haga.   

Abstract

BACKGROUND: According to the 7th edition of the TNM staging system, stage IV metastatic colorectal cancer (CRC) at the time of initial diagnosis is sub-classified into stage IVA or IVB disease. Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival. This retrospective study was undertaken to investigate the overall survival in metastatic CRC patients, focusing on PC patients.
METHODS: We reviewed data on patients with metastatic CRC at initial diagnosis surgically treated between January 2006 and June 2011. A survival analysis was performed paying special attention to PC and sub-classifying patients with PC into three categories according to metastatic sites.
RESULTS: There were 69 stage IVA patients (IVA group) and 83 stage IVB. Among stage IVB patients, 20 had isolated PC (PC-I group), 28 had PC with one or more other sites of metastasis (PC-II group), and 35 had at least 2 metastatic without peritoneal involvement (NPC group). Of 152 stage IV patients, 132 (87 %) underwent resection of the primary tumor and 19 (12 %) underwent radical resection of metastatic disease with microscopic free margins (R0 resection) including 5/20 (25 %) patients in the PC1 group. A total of 139 patients received oxaliplatin-based chemotherapy in a palliative (n = 125), neoadjuvant (n = 3), or adjuvant setting after R0 resection (n = 11). Compared with 36.6 months in the PC-I group, median survival was 32.5 months (P = 0.48) in the IVA group, 14.7 months (P = 0.07) in the PC-II group, and 12.9 months (P < 0.01) in the NPC group.
CONCLUSIONS: The sub-classification of isolated PC into stage IVA instead of IVB might be more appropriate in the era of modern chemotherapy. Further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389285     DOI: 10.1007/s10151-012-0972-9

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  23 in total

1.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Authors:  Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin.

Authors:  Yvonne L B Klaver; Bart J M Leenders; Geert-Jan Creemers; Harm J T Rutten; Victor J Verwaal; Valery E P P Lemmens; Ignace H J T de Hingh
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

3.  Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.

Authors:  J Segelman; F Granath; T Holm; M Machado; H Mahteme; A Martling
Journal:  Br J Surg       Date:  2012-01-27       Impact factor: 6.939

4.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

Review 5.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

6.  Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.

Authors:  Martin R Weiser; Mithat Gönen; Joanne F Chou; Michael W Kattan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

7.  Validation of the seventh edition of the American Joint Committee on cancer tumor node-staging system in patients with colorectal carcinoma in comparison with sixth classification.

Authors:  Jun Seok Park; Gyu-Seog Choi; Suguru Hasegawa; Yoshiharu Sakai; Jung Wook Huh; Hyeong Rok Kim; Sang Gyu Kwak
Journal:  J Surg Oncol       Date:  2012-04-18       Impact factor: 3.454

8.  Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy.

Authors:  Hirotoshi Kobayashi; Masayuki Enomoto; Tetsuro Higuchi; Hiroyuki Uetake; Satoru Iida; Toshiaki Ishikawa; Megumi Ishiguro; Kenichi Sugihara
Journal:  Dig Surg       Date:  2010-11-10       Impact factor: 2.588

9.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

10.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

View more
  1 in total

1.  Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?

Authors:  E Chouillard; V Greco; N Tsiminikakis
Journal:  Tech Coloproctol       Date:  2013-09-06       Impact factor: 3.781

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.